Description

Congestive Heart Disease Marker Tests Market

Congestive heart disease marker tests are diagnostic tests to measure the concentration of the protein to identify the occurrence and disease phase. The cardiac diseases can be prevented by identifying the heart conditions by cardiac biomarker testing is helpful for the immediate diagnosis and treatment. Cardiac biomarkers evaluate the cardiac function and help in identifying the severity and complexity of procedures to treat CVD. The primary indications for the CVD are acute coronary syndrome (ACS) that include congestive heart failure (CHF), angina pectoris (AP) peripheral artery disease (PAD), acute myocardial infarction (AMI) and others.  The causes for CVD are include smoking, high blood pressure, diabetes, inadequate exercise, stress, unhealthy diet, obesity, high blood cholesterol, and alcoholism. The most commonly used cardiac biomarkers for diagnosis of CVD include troponin I and T, CK-MB, BNPs, myoglobin, and IMA, among others.

 

Increase in geriatric population, rise in funding from private-public organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the global market over the forecast period. Moreover, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing, and increase in the adoption of new diagnostic tools by healthcare professionals and cost affordability for patients might propel the global market over the forecast period. However, factors technical problems such as sample collection and storage, stringent regulatory guidelines, lack of reimbursement systems hamper the growth of market over the forecast period.

Global  market is segmented on the basis of product type, test type, application, and end-user

 

Based on product type, the global market has been segmented into the following:

  • Reagents
  • Kits
  • Instruments
  • Chemiluminescence
  • Immunofluorescence
  • ELISA
  • Immunochromatography

 

Based on test type, the global market has been segmented into the following:

  • Myocardial muscle Creatine Kinase (CK-MB)
  • Myoglobin
  • Troponins (T and I)
  • Ischemia Modified Albumin (IMA)
  • NT-proBNP or Brain Natriuretic Peptide (BNP) or
  • Others

 

Based on application, the global market has been segmented into the following:

 

Based on the end-user, the global  market has been segmented into the following:

  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Others

 

Geography

 

 North America

  • US
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

 

Launch of new products, technological advancements, acquisitions and mergers, and collaborations are some key strategies followed by various industry players to increase their share in the congestive heart disease marker test market. For instance, in July 2011, Thermo Fisher Scientific it inked a license agreement with Alere Inc. to develop its novel Thermo Scientific B.R.A.H.M.S. biomarker assays on Alere’s leading point-of-care Triage platform.

 

Geographically, global market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the dominant share owing to increase in the prevalence of congestive heart failures (According to the American Heart Association (AHA), nearly five Mn individuals experience heart failure and about 550,000 new cases are diagnosed each year in the United States). Rising aging population, increase in inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders are the key factors expected to drive the market over the forecast period.

 

Europe holds a major share in global market attributed to increase in the prevalence of congestive heart failure (According to British Heart Foundation (BHF) approximately 7 Mn people are suffering from the various cardiovascular disease in U.K.). Rise in incidence of congestive heart disease in U.K. (approximately 4000 cases per year in new born babies), increase in the research and development, and novel innovations in congestive heart disease biomarker tests might fuel the growth of the market. The Asia-Pacific is expected to exhibit significant growth over forecast period owing to increase in prevalence of Myocardial Infarction, public–private initiatives to increase the awareness related to early cardiac disease diagnosis in physicians and patients.

 

Some of the players in congestive heart disease marker test market are F. Hoffmann-La Roche (Switzerland), Siemens AG (Germany), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Nanogen, Inc. (U.S.), bioMérieux SA (France), Alere, Inc. (U.S.),  LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation, Japan), Randox Laboratories Ltd (U.K.), Ortho Clinical Diagnostics (The Carlyle Group) (U.S.),and Guangzhou Wondfo Biotech Co. Ltd. (China) to name a few.

 

In September 2016, National Institute for Health and Care Excellence developed a Medtech Innovation Briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care

 

Report Outline:

 

  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario


Location

GEOGRAPHY

PBI Location Map

Table of Contents

1. Research Methodology

 

1.1. Secondary and Primary research

1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

 

2. Scope of Study

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

 

3. Executive summary

 

4. Global Congestive Heart Disease Marker Tests Market Dynamics

 

4.1. Drivers

4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

 

5. Unique Features of the Report

 

5.1. Competition analysis

5.2. Novel Biomarker Tests

5.3. Epidemiology

 
6. Global Congestive Heart Disease Marker Tests Market Analysis, By Test Type, 2012 – 2016 and Forecast, 2017 – 2023

 

6.1. Myocardial muscle Creatine Kinase (CK-MB)

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. hs-CRP
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Troponins (T and I)
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Ischemia Modified Albumin (IMA)
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.6. Myoglobin
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.7. Others
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

 

7. Global Congestive Heart Disease Marker Tests Market Forecast, By Application Analysis, 2012 – 2016 and Forecast, 2017 – “2023

 

7.1. Myocardial Infarction

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Acute Coronary Syndrome
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Congestive Heart Failure
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Atherosclerosis
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

 

8. Global Congestive Heart Disease Marker Tests Market Forecast, By End User Analysis, 2012 – 2016 and Forecast, 2017 – 2023

 

8.1. Hospitals

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Clinics
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Diagnostic Centers
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Others
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

 

9. Congestive Heart Disease Marker Tests Market Analysis, By Region, 2012 – 2016 and Forecast, 2017 – 2023

9.1. North America Congestive Heart Disease Marker Tests Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
9.1.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and    Y-o-Y Growth (%)

 

9.1.1.1. Myocardial muscle Creatine Kinase (CK-MB)

9.1.1.2. hs-CRP
9.1.1.3. Troponins (T and I)
9.1.1.4. Ischemia Modified Albumin (IMA)
9.1.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
9.1.1.6. Myoglobin
9.1.1.7. Others
9.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue    (USD Mn) and Y-o-Y Growth (%)

 

9.1.2.1. Myocardial Infarction

9.1.2.2. Acute Coronary Syndrome
9.1.2.3. Congestive Heart Failure
9.1.3.4. Atherosclerosis
9.1.3.5. Others
9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.1.3.1. Hospitals

9.1.3.2. Clinics
9.1.3.3. Diagnostic Centers
9.1.3.4. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.1.4.1. US

9.1.4.2. Canada

 

9.2. Europe Congestive Heart Disease Marker Tests Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023

9.2.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and    Y-o-Y Growth (%)

 

9.2.1.1. Myocardial muscle Creatine Kinase (CK-MB)

9.2.1.2. hs-CRP
9.2.1.3. Troponins (T and I)
9.2.1.4. Ischemia Modified Albumin (IMA)
9.2.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
9.2.1.6. Myoglobin
9.2.1.7. Others
9.2.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue    (USD Mn) and Y-o-Y Growth (%)

 

9.2.2.1. Myocardial Infarction

9.2.2.2. Acute Coronary Syndrome
9.2.2.3. Congestive Heart Failure
9.2.2.4. Atherosclerosis
9.2.2.5. Others
9.2.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.2.3.1. Hospitals

9.2.3.2. Clinics
9.2.3.3. Diagnostic Centers
9.2.3.4. Others
9.2.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.2.4.1. UK

9.2.4.2. Germany
9.2.4.3. France
9.2.4.4. Italy
9.2.4.5. Spain
9.2.4.6. Russia
9.2.4.7. Poland
9.2.4.8. Rest of Europe

 

9.3. Asia-Pacific  Congestive Heart Disease Marker Tests Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023

9.3.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and    Y-o-Y Growth (%)

 

9.3.1.1. Myocardial muscle Creatine Kinase (CK-MB)

9.3.1.2. hs-CRP
9.3.1.3. Troponins (T and I)
9.3.1.4. Ischemia Modified Albumin (IMA)
9.3.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
9.3.1.6. Myoglobin
9.3.1.7. Others
9.3.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue    (USD Mn) and Y-o-Y Growth (%)

 

9.3.2.1. Myocardial Infarction

9.3.2.2. Acute Coronary Syndrome
9.3.2.3. Congestive Heart Failure
9.3.2.4. Atherosclerosis
9.3.2.5. Others
9.3.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.3.3.1. Hospitals

9.3.3.2. Clinics
9.3.3.3. Diagnostic Centers
9.3.3.4. Others
9.3.4. Country Analysis (3013 – 3016) and Forecast (3017 – 3033) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.3.4.1. Japan

9.3.4.2. China
9.3.4.3. India
9.3.4.4. ASEAN
9.3.4.5. Australia & New Zealand
9.3.4.6. Rest of Asia-Pacific

 

9.4. Latin America Congestive Heart Disease Marker Tests Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023

9.4.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.1.1. Myocardial muscle Creatine Kinase (CK-MB)
9.4.1.2. hs-CRP
9.4.1.3. Troponins (T and I)
9.4.1.4. Ischemia Modified Albumin (IMA)
9.4.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
9.4.1.6. Myoglobin
9.4.1.7. Others
9.4.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue    (USD Mn) and Y-o-Y Growth (%)

 

9.4.2.1. Myocardial Infarction

9.4.2.2. Acute Coronary Syndrome
9.4.2.3. Congestive Heart Failure
9.4.2.4. Atherosclerosis
9.4.2.5. Others
9.4.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)

 

9.4.3.1. Hospitals

9.4.3.2. Clinics
9.4.3.4. Diagnostic Centers
9.4.3.5. Others
9.4.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.4.4.1. Brazil
9.4.4.2. Mexico
9.4.4.3. Argentina
9.4.4.4. Venezuela
9.4.4.5. Rest of Latin America
9.5. Middle East & Africa Congestive Heart Disease Marker Tests Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
9.5.1. Test Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and    Y-o-Y Growth (%)
9.5.1.1. Myocardial muscle Creatine Kinase (CK-MB)
9.5.1.2. hs-CRP
9.5.1.3. Troponins (T and I)
9.5.1.4. Ischemia Modified Albumin (IMA)
9.5.1.5. NT-proBNP or Brain Natriuretic Peptide (BNP)
9.5.1.6. Myoglobin
9.5.1.7. Others
9.5.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue    (USD Mn) and Y-o-Y Growth (%)
9.5.2.1. Myocardial Infarction
9.5.2.2. Acute Coronary Syndrome
9.5.2.3. Congestive Heart Failure
9.5.2.4. Atherosclerosis
9.5.2.5. Others
9.5.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.3.1. Hospitals
9.5.3.2. Clinics
9.5.3.3. Diagnostic Centers
9.5.3.4. Others
9.5.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
9.5.4.1. Gulf Cooperation Council (GCC) Countries
9.5.4.2. Israel
9.5.4.3. South Africa
9.5.4.4. Rest of MEA
10. Competition Landscape
10.1. Strategic Dashboard of Top Market Players
10.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
10.2.1. F. Hoffmann-La Roche
10.2.2. Siemens Healthcare GmbH
10.2.3. Abbott Laboratories
10.2.4. ELITechGroup
10.2.5. bioMérieux SA
10.2.6. Alere Inc.,
10.2.7.  LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation)
10.2.8. Randox Laboratories Ltd
10.2.9. Ortho Clinical Diagnostics (The Carlyle Group)
10.2.10. Guangzhou Wondfo Biotech Co. Ltd.

 Disclaimer

The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

 

Request Customisation

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

Ask An Analyst

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX